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A20 prevents chronic liver inflammation and cancer by
protecting hepatocytes from death
L Catrysse1,2,8, M Farhang Ghahremani1,2,8, L Vereecke1,2, SA Youssef3, C Mc Guire1,2, M Sze1,2, A Weber4, M Heikenwalder5,6,
A de Bruin3,7, R Beyaert1,2 and G van Loo*,1,2
An important regulator of inflammatory signalling is the ubiquitin-editing protein A20 that acts as a break on nuclear factor-κB
(NF-κB) activation, but also exerts important cytoprotective functions. A20 knockout mice are cachectic and die prematurely due to
excessive multi-organ inflammation. To establish the importance of A20 in liver homeostasis and pathology, we developed a novel
mouse line lacking A20 specifically in liver parenchymal cells. These mice spontaneously develop chronic liver inflammation but
no fibrosis or hepatocellular carcinomas, illustrating an important role for A20 in normal liver tissue homeostasis. Hepatocyte-
specific A20 knockout mice show sustained NF-κB-dependent gene expression in the liver upon tumor necrosis factor (TNF)
or lipopolysaccharide injection, as well as hepatocyte apoptosis and lethality upon challenge with sublethal doses of TNF,
demonstrating an essential role for A20 in the protection of mice against acute liver failure. Finally, chronic liver inflammation and
enhanced hepatocyte apoptosis in hepatocyte-specific A20 knockout mice was associated with increased susceptibility to
chemically or high fat-diet-induced hepatocellular carcinoma development. Together, these studies establish A20 as a crucial
hepatoprotective factor.
Cell Death and Disease (2016) 7, e2250; doi:10.1038/cddis.2016.154; published online 2 June 2016
Apoptotic cell death plays an important role in liver disease,
and tumor necrosis factor receptor-1 (TNFR1) and Fas (CD95)
are the most prominent cell death receptors involved.1 Both
TNF and Fas ligand initiate a signalling pathway leading to
apoptosis through receptor Fas-associated death domain
(FADD) recruitment and activation of procaspase-8 leading to
downstream procaspase-3 activation. TNF is distinct from Fas
signalling as it first activates nuclear factor-κB (NF-κB) and
c-jun N-terminal kinase(JNK).2 The transcription factor NF-κB
controls cytoprotective activities by inducing the expression
of important anti-apoptotic genes including A20, Bcl-xL and
c-FLIP, and through inhibition of prolonged JNK activation.3
However, when protective NF-κB activation is compromised,
the activated TNF receptor complex will induce the activation
of an apoptotic cascade.2 The involvement of TNF and Fas
signalling in liver apoptosis was previously confirmed in
transgenic mice overexpressing a dominant-negative FADD
mutant, and in hepatocyte-specific caspase-8 deficient mice,
showing a complete rescue from TNF- and Fas-induced liver
failure.4–6 Besides apoptosis, which is generally considered
a non-inflammatory cell death mode due to rapid clearance
of apoptotic cells by phagocytes, TNF can also induce
necroptosis, which is characterized by cellular swelling and
membrane leakage, inducing strong inflammatory responses
and thus highly relevant for many types of liver diseases.1
Next to acute liver failure, which can be caused by hepato-
toxins, foodborne poisons, alcohol intoxication or infections,
and is characterized by massive hepatocyte apoptosis
associated with life-threatening consequences, most liver
pathologies result from chronic disease processes involving
inflammation, continuous hepatocyte apoptosis and compen-
satory tissue regeneration, promoting the development of liver
fibrosis, cirrhosis and eventually hepatocellular carcinoma
(HCC). Many of the inflammatory mediators involved in these
liver diseases are targets or activators of NF-κB. However,
besides its crucial contribution to these detrimental inflamma-
tory reactions in liver, NF-κB also contributes to liver homeo-
stasis and wound-healing processes.7
The NF-κB responsive and ubiquitin-editing protein A20
(also referred to as TNF alpha-induced protein 3 or TNFAIP3)
is essential for the termination of NF-κB signalling in response
to TNF and microbial products such as lipopolysaccharide
(LPS) and muramyl dipeptide,8,9 but also negatively regu-
lates TNF-induced apoptosis.10,11 Interestingly, A20 has
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been identified as a susceptibility locus for multiple immuno-
pathologies,12 including autoimmune hepatitis.13 Using A20
heterozygous mice, or mice that transiently overexpress an
A20 cDNA, A20 in liver has been shown to be contributing
to liver regeneration after partial hepatectomy14–17 and
acute toxic hepatitis18 through combined anti-apoptotic, anti-
inflammatory and pro-proliferative functions.19
To study the role of endogenously expressed A20 in liver
development and conditions of liver inflammation and hepato-
carcinogenesis, we generated hepatocyte-specific A20
knockout mice. Here we show that, consistent with its role in
NF-κB signalling, hepatocyte-specific A20 deficiency sensi-
tizes mice to develop spontaneous liver inflammation,
demonstrating a physiological role for A20 in regulating liver
immune homeostasis. In agreement, A20 deficient hepato-
cytes display sustained NF-κB signalling and gene expression
upon TNF or LPS challenge. Hepatocyte-specific A20 knock-
out mice are also hypersensitive to TNF-induced hepatocyte
apoptosis and lethality, demonstrating an important cyto-
protective function for A20 in hepatocytes. Finally, chronic
liver inflammation and hepatocyte apoptosis sensitizes liver
parenchymal cell-specific A20 knockout mice to the develop-
ment of HCC in experimental models.
Results
Generation of mice lacking A20 specifically in liver
parenchymal cells. Mice with a conditional A20 allele, in
which exons IV and V of A20 are flanked with two LoxP sites,
were generated as described.11 In order to study the role
of A20 in hepatocytes, we crossed the A20FL/FL mice with
a transgenic mouse line that expresses Cre under the control
of the liver-specific albumin/alpha-fetoprotein promoter/
enhancer (Alfp-Cre) and mediates efficient Cre recombina-
tion in liver parenchymal cells20,21 (Supplementary Fig. S1).
Hepatocyte-specific A20 knockout (A20FL/FL/Alfp-Cre, liver
parenchymal cell-specific A20 knockout, A20LPC-KO) mice
were born with normal Mendelian segregation and reached
adulthood without any evidence of hepatic defects. Immuno-
blot analysis of liver protein extracts revealed efficient
ablation of A20 in livers of A20LPC-KO mice (Figure 1a).
Phenotype of hepatocyte A20 deficient mice. A20LPC-KO
mice appear healthy and phenotypic analysis up to the age
of 18 months revealed no obvious pathologies. Macroscopic
dissection of livers from A20LPC-KO mice revealed normal
tissue morphology with absence of inflammatory foci,
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Figure 1 Molecular and histological analysis of hepatocyte-specific A20 knockout mice. (a) Western blot analysis for A20 expression in liver extracts from
individual hepatocyte-specific A20 knockout (LPC-KO) and control WT littermate mice, either or not injected with recombinant mouse TNF. *, unspecific. (b) Representative
pictures from hematoxylin and eosin-stained liver sections from hepatocyte-specific A20 knockout (A20LPC-KO) and control WT littermate mice. White arrow: Macro-
vesicular steatosis, yellow arrow: inflammatory foci, red arrow: balloon cell. (c) Immunostaining for infiltrating B cells (B220), T cells (CD3) and macrophages (F4/80), and
(d) Ki67 staining for proliferating cells. (e) Representative picture of Picro Sirius red-stained sections from A20LPC-KO and control WT littermate mice. Scale bar= 100 μm.
WT, wild type
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nodules or tumors. However, histological examination of liver
sections from 25-week-old A20LPC-KO mice revealed clear
signs of chronic hepatitis and steatosis (Figure 1b, Table 1),
and increased B, T cell and macrophage infiltration as
demonstrated by anti-B220, -CD3 and –F4/80 immunohisto-
chemistry, respectively (Figure 1c, Supplementary Fig. S2).
Also, hepatocyte proliferation, as assessed by Ki67 staining,
was strongly increased in livers from A20LPC-KO mice, com-
pared with control mice (Figure 1d). In old mice (41 year of
age), the severity of lobular inflammation, numbers of inflam-
matory foci and non-alcoholic fatty liver disease (NAFLD)
activity (NAS) score (sum of steatosis+ballooning degene-
ration+inflammation) were significantly increased in the
A20LPC-KO mice when compared with the control group
(Figure 1b, Table 1). No evidence of spontaneous fibrosis,
as assessed by Picro Sirius red staining (Figure 1e, Table 1),
or neoplasia was present in any of the examined mice. Taken
together, these results demonstrate that conditional dele-
tion of A20 in parenchymal liver cells results in a sponta-
neous mild to moderate liver inflammation and steatosis,
however, without development of fibrosis or HCCs even at
old age.
We next challenged A20LPC-KO mice and control littermates
with low dose LPS or TNF by intraperitoneal (i.p.) injection,
and analysed their livers for altered inflammatory responses.
In contrast to TNF that directly activates hepatocytes through
binding to its receptor expressed on these cells, LPS can
indirectly induce TNF release by Kupffer cells through binding
to TLR4 expressed on these cells. Consistent with A20’s role
as an inhibitor of NF-κB-dependent gene expression, A20-
deficient liver tissue displayed sustained degradation of the
NF-κB inhibitory protein IκBα and significantly higher mRNA
expression of TNF, IL6, IκBα and MCP1 in response to LPS
than wild-type cells (Figures 2a and b). Next to the
hyperactivation of NF-κB signalling, analysis of other signalling
events also showed enhanced JNK phosphorylation in LPS-
treated A20LPC-KO mice compared with wild-type controls
(Figure 2b). The levels of phosphorylated ERK, however, were
not different between both mouse lines (Figure 2b). Similar
observations were made in mice challenged with low dose
TNF injection (Supplementary Fig. S3).
Together, these results demonstrate a physiological role
for A20 in restricting pro-inflammatory signalling in the liver.
A20 protects hepatocytes from apoptosis in experi-
mental hepatitis. Independent from its role as a modulator
of NF-κB signalling, A20 functions as an anti-apoptotic
protein in several cell types, including enterocytes11 and
hepatocytes.19 To investigate whether A20 protects hepato-
cytes from TNF-mediated apoptosis in vivo, we injected mice
with a sublethal (10 μg) dose of recombinant mouse TNF. At
this dose, TNF normally induces hepatoprotective mechan-
isms through NF-κB-mediated induction of anti-apoptotic
genes such as A20 and Bcl-XL, protecting mice from TNF-
induced liver toxicity7 (Figures 2a and b and Supplementary
Fig. S4). In contrast to control mice, which all resist the TNF
challenge and only show a modest drop in body temperature,
A20LPC-KO mice display severe hypothermia, and were
euthanized between 12 and 30 h post-injection for ethical
reasons (Figures 3a and b). Histological and microscopic
signs of massive liver destruction could be observed in
TNF-injected A20LPC-KO mice. The architecture of the liver
parenchyma was completely destroyed 6 h post-injection,
with clearly visible pyknotic nuclei and numerous red blood
cells, in contrast to control liver tissue which looked
completely normal (Figure 3c). Liver cell death was also
confirmed by TUNEL staining, where many hepatocytes in
A20LPC-KO liver tissue stain positive in contrast to very few
TUNEL-positive hepatocytes in control tissue (Figure 3d).
Massive liver damage upon TNF challenge in A20LPC-KO mice
was associated with release of liver-specific enzymes
aspartate transaminase (AST) and alanine transaminase
(ALT) in the blood (Figure 3e). Also the pro-inflammatory
cytokine IL-6 was abundantly present in serum from TNF-
injected A20LPC-KO mice, while much less abundant in serum
from control littermate mice (Figure 3f). In line with these
observations, procaspase-3 processing and caspase-3 acti-
vity could be detected in livers of A20LPC-KO mice but not of
control mice, as shown by a caspase-3-specific enzymatic
DEVD-activity assay (Figures 3g and h). Together, these data
identify A20 as an essential protein protecting mice from
TNF-induced hepatocyte apoptosis and acute liver failure
in vivo.
A20LPC-KO hepatocytes die from TNF-induced FADD-
dependent apoptosis. In the absence of A20, hepatocytes
are hyper-responsive to TNF-induced apoptosis. To confirm
the direct cytotoxic effect of TNF inducing death receptor-
dependent apoptosis of hepatocytes, we generated A20/
FADDLPC-DKO mice by crossing the A20LPC-KO line with mice
having a floxed FADD allele (FADDFL/FL).22 These mice
lack both A20 and FADD specifically in liver parenchymal
cells (Supplementary Fig. S5). Fas-associated death domain
protein is a key adaptor protein signalling to apoptosis from
Table 1 Average scores of selected lesions in A20LPC-KO mice (KO) and control (WT) littermates
Group Lesions
Steatosis Ballooning Lobular inflammationa NAS Neoplasia % Fibrotic area
WT (n= 5) 20 weeks 0.70 0.12 0.20 (1) 1.00 No 0.35± 0.05
KO (n=7) 20 weeks 0.71 0.07 0.50 (2) 1.29 No 0.44± 0.04
WT (n= 4)4 1 year 0.12 0 0.12 (0.25) 0.25 No NA
KO (n=2)4 1 year 1.50 0.75 0.5 (2.5) 2.75 No NA
Abbreviations: KO, knockout; WT, wild type
aAverage number of inflammatory foci per 5 × 20 fields. N.A., not analysed
A20 in liver inﬂammation and pathology
L Catrysse et al
3
Cell Death and Disease
activated death receptors, including TNFR1.23 As such, liver-
specific FADD-deficient mice (FADDLPC-KO) are insensitive
to anti-Fas and LPS+galactosamine (GalN)-induced TNFR1-
mediated liver toxicity24,25 (Supplementary Fig. S6). To eval-
uate the contribution of FADD-dependent signalling to
the lethal phenotype seen in A20LPC-KO mice injected with
TNF, we challenged A20/FADDLPC-DKO mice and A20LPC-KO
littermates with a sublethal dose of TNF, as described
above. In contrast to A20LPC-KO mice, which all died between
8 and 25 h post-injection, A20/FADDLPC-DKO mice all support
this dose of TNF and only show a modest drop in body
temperature similar to wild-type control littermate mice
(Figures 4a and b). In agreement, liver damage, as detec-
ted by histology and serum ALT and AST levels, was
strongly reduced in A20/FADDLPC-DKO mice, compared with
A20LPC-KO mice (Figures 4c and d). Also IL-6 levels were
reduced in A20/FADDLPC-KO mice (Figure 4e). Finally,
procaspase-3 processing could only be detected after TNF
challenge in the liver of A20LPC-KO mice, not in control or
A20/FADDLPC-DKO mice (Figure 4f). These data clearly
confirm the essential role of A20 in protecting hepatocytes
from FADD-dependent TNF-induced apoptosis.
Hepatocyte-specific A20 deletion enhances suscepti-
bility to chemically and high fat diet induced
hepatocarcinogenesis. It has become clear that canonical
and non-canoncial NF-κB signalling has a critical role in
cancer development and progression.26–28 NF-κB controls
pro-survival gene expression and the ability of malignant cells
to resist apoptosis-based tumor surveillance mechanisms.
Moreover, NF-κB also regulates tumor angiogenesis and
invasiveness. As a consequence, constitutively active NF-κB
can be observed in many types of cancer, including
hepatocellular cancer (HCC). Since A20LPC-KO mice develop
a condition of chronic liver inflammation and are sensitized to
hepatocyte apoptosis, we wondered whether A20LPC-KO mice
are also sensitized to HCC development. Since these mice
do not develop spontaneous HCC (Figure 1), we subjected
A20LPC-KO mice and control littermates to the chemical
carcinogen diethylnitrosamine (DEN). A single injection of
the tumor initiator DEN in 15-day-old C57BL/6 mice induces
hepatocyte DNA damage resulting in HCC with a course of
development similar to human HCC.29 Although female
mice are less sensitive than males to DEN-induced
hepatocarcinogenesis,29 only part of the males displayed
typical HCC at the age of 40 weeks, but no significant
differences in tumor-occupied liver area or number of
macroscopically detectable tumors could be observed
between DEN-injected A20LPC-KO and control littermate mice
(Supplementary Fig. S7). In contrast, A20LPC-KO female mice
developed more and larger tumors and had significantly
larger tumor-occupied area compared with wild-type
littermates 70 weeks after DEN injection (Figures 5a-c and
data not shown). Also hepatocyte proliferation, as assessed
by Ki67 staining, and immune cell infiltration was increased in
livers from DEN-treated A20LPC-KO mice, compared with
A20
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Figure 2 Increased cytokine expression, NF-κB activation and JNK activation in A20LPC-KO mice. (a) Quantitative RT-PCR analysis of NF-κB response gene mRNA levels in
the liver of 8-week-old A20LPC-KO (n= 3) and WT (n= 3) littermate mice 120 min after PBS or LPS injection. Expression levels were normalized to reference genes HPRTand
GAPDH using qbase+ software. Results are expressed as mean± s.d. *,Po0.05. (b) Liver protein extracts from 8-week-old LPS-injected A20LPC-KO and WT mice subjected to
immunoblot using antibodies detecting A20, JNK, phospho-JNK, IκBα, phospho-IκBα, Erk, phospho-Erk and actin. JNK, c-jun N-terminal kinase; LPS, lipopolysaccharide;
WT, wild type
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control mice (Figure 5d). We next subjected A20LPC-KO and
control littermate mice to a high fat diet (HFD). Increased
hepatocyte fat uptake by long-term HFD feeding leads to
NAFLD that can progress to fibrosis, cirrhosis and even
HCC.30 Thus, increased fat uptake represents a risk factor for
HCC development. In addition pro-inflammatory cytokines
such as IL1β, IL-6 and TNF have been shown to promote
HFD-induced obesity and tumorigenesis.31 A20LPC-KO mice
fed on HFD for 20 weeks exhibited a marked increase in the
severity of lobular inflammation, ballooning, degeneration and
overall NAS (sum of steatosis+ballooning+inflammation)
when compared with littermate controls on HFD (Table 2).
In mice fed with HFD for 1 year, the severity of lobular
inflammation, numbers of inflammatory foci and NAS further
increased and was significantly more severe in A20LPC-KO
mice compared with the control wild-type group. Moreover,
three out of seven HFD- A20LPC-KO mice had multiple benign
and malignant hepatic tumors (hepatocellular adenoma, HCC
and hepatoblastoma), while no evidence of neoplasia
was present in all HFD-treated wild-type mice (Figures 5e
and f and Table 2). Also, liver sections from A20LPC-KO mice
fed on HFD displayed more hepatocyte proliferation and
immune cell infiltration compared with control mice on HFD
(Figure 5g).
In conclusion, loss of A20 in hepatocytes increases the
susceptibility to DEN- and HFD-induced hepatocarcino-
genesis.
Discussion
To investigate the role of A20 in the adult liver and in conditions
of chronic liver inflammation (hepatitis) and hepatocarcino-
genesis, we generated mice with hepatocyte-specific deletion
of A20. A20LPC-KO mice appear healthy and show no obvious
spontaneous pathologies. However, dissection of livers from
hepatocyte A20 knockout mice revealed low grade chronic
liver inflammation without development of fibrosis or HCCs
even at old age. Consistent with the essential role of A20 as a
negative feedback regulator of NF-κB signalling, A20-deficient
liver tissue displayed sustained NF-κB-dependent gene
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expression upon TNF or LPS challenge, demonstrating an
important role for A20 in the control of inflammatory reactions
in liver.
We previously described A20 as an anti-apoptotic factor in
intestinal epithelial cells essential to prevent TNF-induced
apoptosis.11,32 Also in hepatocytes, as shown in this study,
A20 mainly acts as a protective factor. As a consequence,
hepatocyte-specific A20 knockout mice are highly sensitive to
a normally sub-lethal dose of TNF, inducing hypothermia and
lethality caused bymassive hepatocyte apoptosis. In most cell
types, TNF-induced cell death requires inhibition of NF-κB-
induced expression of pro-survival genes. A20-deficient
hepatocytes and IECs, however, undergo TNF-induced
apoptosis with intact NF-κB activity, which suggests that A20
is an essential anti-apoptotic protein induced by NF-κB upon
TNF stimulation in these cells.
Although the molecular mechanism by which A20 restricts
NF-κB activation is well characterized,12 the mechanism of its
anti-apoptotic functions has long been unclear. A20 was
identified as part of the death-inducing signalling complex,
being recruited after activation of death receptors, where it
physically interactswith polyubiquitinated caspase-8.33 In vitro
studies suggested that A20 could probably act as a
deubiquitinase, inhibiting caspase-8-induced apoptosis.33
A20 has also been shown to increase polyubiquitination of
RIP1, enabling RIP1 binding to the caspase-8 protease
domain to inhibit its dimerization, cleavage and activation,34
and yet another study suggested that A20 blocks TNF-induced
apoptosis through suppression of the JNK by targeting
apoptosis signal-regulating kinase 1 for proteasomal
degradation.35 However, very recently, A20 was shown to
inhibit cell death by stabilization of linear ubiquitin chains in the
death receptor complex, protecting them from cleavage by
competing deubiquitinases.36,37
The liver has remarkable regenerative capacity, and
surviving hepatocytes massively start proliferating following
hepatic loss or injury in order to restore liver function and
mass. Mechanistically, it is still unclear if compensatory
proliferation following cytotoxic injury differs from liver regen-
eration after hepatectomy. In different mouse models, how-
ever, including the TAK1 and NEMO liver-specific knockout
mouse model,38–40 hepatocyte death is the driving force
triggering proliferation, favouring hepatocarcinogenesis.1
Hepatocyte cell death thus represents a tumor-promoting
condition, mediated by compensatory hepatocyte proliferation
and inflammation. Since A20 controls both inflammatory and
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Figure 5 Hepatocyte-specific A20 deletion enhances susceptibility to chemically induced and HFD-induced hepatocarcinogenesis. (a-d) Female A20LPC-KO and control
littermate mice (WT) were injected with DEN at day P15 and were sacrificed 70 weeks after DEN injection. (a) Representative pictures of livers from hepatocyte-specific A20
knockout (A20LPC-KO) and control WT littermate mice. (b) Percentage of tumor occupied liver area, and (c) numbers of tumors size 1-2 mm and42 mm in livers. *,Po0.05.
(D) Immunostaining for proliferating cells (Ki67) and infiltrating immune cells (CD3, CD45). Scale bar= 100 μm. T, tumor area. (e-g) Male A20LPC-KO and control littermate mice
(WT) were fed with an HFD for 1 year. Representative picture of a hepatoblastoma (arrows) recorded in HFD-A20LPC-KO mouse (e). Representative picture of a hepatocellular
adenoma (arrows) recorded in HFD-A20LPC-KO mouse (f). Non-neoplastic tissue is depicted by asterisk. The right pictures are a higher magnification to the boxed areas.
(g) Immunostaining for proliferating cells (Ki67) and infiltrating immune cells (CD3, CD45). Scale bar= 100 μm. T, tumor area. DEN, diethylnitrosamin; HFD, high fat diet;
WT, wild type
Table 2 Average scores of selected lesions in A20LPC-KO mice (KO) and control (WT) littermates
Group Lesions
Steatosis Ballooning Lobular inflammationa NAS Neoplasia
HFD-WT (n= 6) 20 weeks 1.58 0.16 0.91 (4.16) 2.66 No
HFD-KO (n= 5) 20 weeks 1.70 0.40 1.30 (7.20) 3.40 No
HFD-WT (n= 4)4 1 year 2.38 1.00 1.00 (5.25) 4.37 No
HFD-KO (n= 7)4 1 year 2.29 1.07 1.37 (6.43) 4.57 H, HCC, HB
Abbreviations: H: Hepatocellular adenoma; HB, hepatoblastoma; HCC, hepatocellular carcinoma; HFD, high fat diet, KO, knockout, WT, wild type
aAverage number of inflammatory foci per 5 × 20 fields
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anti-apoptotic activities in the liver, hepatocyte-specific A20
knockout mice are also sensitized to the development of
hepatocellular cancer.
Previous studies have identified A20 as a tumour suppres-
sor protein in B cells where its inactivation leads to constitutive
or aberrant NF-κB activation mediating increased cell pro-
liferation and survival of subsets of B-lineage lymphomas.41–43
Also in the intestine, A20 acts as a tumor suppressor for colon
carcinogenesis.32,44 In other cell types, however, A20 has
been ascribed pro-tumorigenic activities, likely connected to
its anti-apoptotic functions.12 These observations suggest that
depending on the cell type and tumor stage, A20 may act as a
tumor suppressor or a tumor enhancer. In the context of the
liver, A20 was found to be preferentially expressed in hepatitis
B virus-related HCC cell lines and HCC clinical tissues,
contributing to cellular proliferation and survival,45,46 suggest-
ing A20 as a tumor-promoting agent. This is in contrast to
a recent study in which A20 was identified as a tumor
suppressor in the progression and metastasis of HCC through
a mechanism involving inhibition of expression of the EMT-
related gene Twist1 via suppression of NF-κB activation.47 Our
in vivo findings in mice, however, establish A20 as a crucial
protective and tumor suppressive factor in liver, and suggest
that A20 deficiency or defects in its activity in humans might
sensitize to the development of liver disease and liver cancer
in specific contexts. This may be the case in patients bearing
specific mutations or polymorphisms in the A20 locus, making
them vulnerable to develop chronic liver diseases such as
alcoholic liver disease, NAFLD and viral hepatitis, conditions
known to promote the development of cirrhosis and HCC.
Moreover, A20 has been identified as a susceptibility gene for
autoimmune hepatitis,13 a diseasewhich may also lead to liver
failure, cirrhosis and HCC.48
In conclusion, we here described the dual importance of
A20 in hepatocytes. On one hand, A20 negatively regulates
NF-κB activation and inflammatory signalling. On the other
hand, A20 acts as a major cytoprotective protein for hepato-
cytes in inflammatory and cytotoxic conditions. As a conse-
quence, hepatocyte A20-deficient mice showsustainedNF-κB
signalling, chronic liver inflammation, hepatocyte death and
eventually leading to HCC development.
Materials and Methods
Generation of tissue-specific A20-deficient mice. Conditional
A20/tnfaip3 and FADD knockout mice were generated as described before.11,22
A20FL/FL mice were crossed with Alfp-Cre transgenic mice20,21 to generate a
hepatocyte-specific A20 knockout mouse (A20LPC-KO). Experiments were performed
on mice backcrossed into the C57BL/6 genetic background for at least five
generations. Mice were housed in individually ventilated cages in the specific
pathogen-free animal facility of the VIB Inflammation Research Center. All
experiments on mice were performed according to institutional, national and
European animal regulations.
Liver injury. All experiments were performed on pathogen-free male mice
between 8 and 10 weeks of age. E. coli-derived recombinant mTNF had a specific
activity of 9.46 × 107 IU/mg, and was produced and purified to homogeneity in our
laboratory. Endotoxin levels did not exceed 1 ng/mg protein. TNF was administered
i.p. at concentrations of 1 μg or 10 μg per 25 g of body weight. Serum ALTand AST
levels were measured in the Laboratory of Clinical Biology of the University Hospital
Gent, according to standard procedures. For diet studies, mice received irradiated
standard diet (10% kcal fat, Research Diets Inc., D12450B) or irradiated HFD
(60% kcal fat, Research Diets Inc., D12492) from the age of 8 weeks. For liver
carcinogenesis studies, 15-day-old A20LPC-KO mice and control littermates were
injected i.p. with 20 mg/kg DEN (Sigma, St. Louis, MO, USA). After 60 weeks, all
mice were sacrificed and their livers removed. Percentage tumor area was
measured, and externally visible tumors (1-2 mm and42 mm) were counted by
stereomicroscope.
Western blot analysis. Cells and liver tissue were homogenized using E1A
lysis buffer (50 mM HEPES pH7.6; 250 mM NaCl; 5 mM EDTA; 0.5% NP40).
Protein lysates were prepared from liver samples, and 40 μg lysates were sepa-
rated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred
to nitrocellulose and analysed by immunoblotting. Membranes were probed with
the following antibodies: anti-A20 (Santa Cruz Biotechnologies, Dallas, TX, USA),
anti-caspase-3 (Cell Signaling Technology, Danvers, MA, USA), anti-cleaved
caspase-3 (Cell Signaling Technology), JNK (Santa Cruz Biotechnologies),
phospho-JNK (Cell Signaling Technology), IκBα (Santa Cruz Biotechnologies),
phospho-IκBα (Cell Signaling Technology), Erk (Cell Signaling Technology),
phospho-Erk (Cell Signaling Technology) and anti-actin (Santa Cruz Biotechnolo-
gies). As secondary antibodies, anti-rabbit-HRP, anti-mouse-HRP and anti-goat-
HRP were used (Amersham Bioscience, Buckinghamshire, UK).
Apoptosis assays. Apoptosis was analysed by fluorescence microscopy
using an in situ cell death detection kit (Roche Diagnostics, Basel, Switzerland).
Caspase activity was measured by incubation of 25 μg tissue homogenate with
50 μM acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (Ac-DEVD-amc) (Peptide
Institute, Osaka, Japan) in 150 μl cell-free system buffer (10 mM HEPES–NaOH
pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4, 0.5 mM
EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM PMSF, 1 mM dithiothreitol). The
release of fluorescent 7-amino-4-methylcoumarin was measured for 50 min at 2-min
intervals by fluorospectrometry at 360 nm excitation and 480 nm emission
wavelength, and the maximal rate of increase in fluorescence was calculated
(Δfluorescence/min) (Cytofluor; PerSeptive Biosystems, Cambridge, MA).
Histological analysis. Histology was performed on paraffin-embedded
(3 μm) or frozen tissue sections (5 or 10 μm). Briefly, livers were dissected and
fixed in 4% paraformaldehyde and embedded in paraffin. Liver sections were
examined for the presence of histopathologic lesions and scored as follows: for
steatosis (amount of lipid accumulation), grade 0o5%; 1= 5-33%; 2= 33-66%;
3=466% with 0.5 interval; location of steatosis in hepatic lobule, 0= zone 3;
1= zone 1; 2= azonal; 3= panacinar; microvesicular steatosis, 0= not present;
1= present; percentage of hepatocytes affected by microvesicular steatosis (MI%),
compared with hepatocytes affected by macrovesicular steatosis; hepatocellular
ballooning, 0= none; 1= few balloon cells; 2= many cells/prominent ballooning
with 0.5 interval; lobular inflammation, 0= none; 1=o2 foci per 200 × ; 2= 2-4
foci; 3=44 average foci/200 × field; with 0.5 interval; portal inflammation,
Pigmented macrophages, Oval cell proliferation, Anisokaryosis, and additional
lesions: Scored semi-quantitatively on a scale of 0 to 5. Scores were given as
absent (0), subtle (1), mild (2), moderate (3), severe (4) and marked (5) for each
criteria with 0.5 interval. The NAFLD activity score (NAS) was calculated as
previously described.49,50 Slides were examined unbiased by two board-certified
pathologists. Sections (2 μm) of livers (fixed in 4% paraformaldehyde and
paraffin-embedded) were stained with hematoxylin/eosin or various antibodies.
Incubation in Ventana buffer and staining was performed on a NEXES immuno-
histochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit
(Ventana/Roche, Mannheim, Germany) or on a Bond MAX (Leica GmBH,
Heidelberg, Germany). CD3, B220, F4/80 and Ki67 antibodies were applied as
recently published.28 For analysis of fibrosis, slides were stained with Picro sirius red,
and three × 10 digital images were selected randomly from every section and images
were analysed using in-house developed software to quantify the percentage of
fibrosis compared with the total amount of tissue within an image.
Quantitative real-time PCR. Total RNA from mouse liver samples was
isolated and lysed in RNA lysis buffer (Aurum Total RNA Mini kit, Bio-Rad
Laboratories, Hercules, CA, USA) on ice for 5 min. One μg RNA was purified using
the Aurum Total RNA Mini kit (Bio-Rad Laboratories) and cDNA synthesis was
performed using the iScript cDNA synthesis kit (Bio-Rad Laboratories) according to
the manufacturer’s instructions. 10 ng of cDNA was used for quantitative PCR in a
total volume of 10 μl with LightCycler 480 SYBR Green I Master Mix (Roche) on a
LightCycler 480 (Roche). Real-time PCR reactions were performed in triplicates.
The following mouse-specific primers were used (5′-3′): HPRT forward,
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AGTGTTGGATACAGGC
CAGAC; HPRT reverse, CGTGATTCAAATCCCTGAAGT; A20 forward, AAACCAAT
GGTGATGGAAACTG; A20 reverse, GTTGTCCCATTCGTCATTCC; IκBα forward,
GTAACCTACCAAGGCTACTC; IκBα reverse, GCCACTTTCCACTTATAATGTC; TNF
forward, ACCCTGGTATGAGCCCATATAC; TNF reverse, ACACCCATTCCCTTCAC
AGAG; IL1β forward, CACCTCACAAGCAGAGCACAAG; IL1β reverse, GCATTAGA
AACAGTCCAGCCCATAC; IL-6 forward, GAGGATACCACTCCCAACAGACC; IL-6
reverse, AAGTGCATCATCGTTGTTCATACA; MCP1 forward, GCATCTGCCCTAAG
GTCTTCA; MCP1 reverse, TGCTTGAGGTGGTTGTGGAA. Values were normal-
ized to the level of HPRT and GAPDH mRNA, and analysed using qBase+ software
(Biogazelle, Gent, Belgium).
Statistical analysis. Results are expressed as the mean± s.e.m. Statistical
significance between experimental groups was assessed using an unpaired
two-sample Student t-test.
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